Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (Nasdaq: PHVS) presented its drug development approach for treating hereditary angioedema (HAE) at the Kinin 2022 Conference in France. The symposium highlighted PHVS416 and PHVS719, two oral therapies designed for on-demand and prophylactic treatment. Key findings showed PHVS416 is 25-fold more potent than icatibant, with rapid onset and longer half-life. The Phase 2 RAPIDe-1 study for PHVS416 has reached target enrollment, while the Phase 2 CHAPTER-1 trial continues. Pharvaris aims to provide better treatment alternatives for HAE patients.

Pharvaris (Nasdaq: PHVS) announced its participation in the hae day :-) 2022, a global awareness initiative for hereditary angioedema (HAE). The company engaged its workforce in a 30-day activities challenge, collectively logging over 2 million steps to raise awareness for HAE. CEO Berndt Modig emphasized the company's commitment to improving outcomes for HAE patients through innovative treatments. HAE is a rare genetic condition affecting between 1:50,000 to 1:10,000 individuals globally, causing unpredictable and often life-threatening swelling.

Pharvaris (Nasdaq: PHVS) has appointed Joan Schmidt, J.D., as Chief Legal Officer, effective June 1, 2022. With over 20 years of biopharmaceutical experience, Schmidt will oversee legal activities supporting the company's drug development and commercialization strategies. Previously, she was General Counsel at Arena Pharmaceuticals, aiding in its acquisition by Pfizer for $6.7 billion. Her expertise will enhance Pharvaris' ability to advance its oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE) treatment.

Pharvaris (Nasdaq: PHVS) has achieved its target enrollment in the RAPIDe-1 Phase 2 study of PHVS416, focused on treating HAE attacks, with top-line data expected in 4Q22. Additionally, the company is enrolling patients in the Phase 2 HAE CHAPTER-1 study for prophylactic treatment, also anticipating data in 4Q22. Pharvaris reported a strong liquidity position with €194.8 million in cash as of March 31, 2022, though R&D and G&A expenses increased, leading to a loss of €16.0 million for Q1 2022.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), has announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas from May 10-12, 2022. The company's presentation is scheduled for May 12, 2022, at 10:00 AM PDT (7:00 PM CEST). A live webcast will be accessible on its website, with a replay available for 30 days post-event.

Pharvaris (Nasdaq: PHVS), a clinical-stage company specializing in oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), announced its participation in two investor conferences in April 2022. The 21st Annual Needham Virtual Healthcare Conference will take place on April 11, 2022, at 2:45 PM CEST, while the Kempen 14th Life Sciences Conference is scheduled for April 21, 2022, at 3:00 PM CEST in Amsterdam. Investors can access webcasts of the presentations on the company's website, with replays available for 30 days post-event.

Pharvaris (PHVS) reported significant advancements in its clinical development, including the successful Phase 1 study of PHVS719, confirming its suitability for once-daily dosing. The FDA granted orphan drug designation to PHA121, enhancing its potential market position. Ongoing Phase 2 trials, RAPIDe-1 and CHAPTER-1, target on-demand and prophylactic treatment of hereditary angioedema (HAE), with top-line data expected in 4Q22. The company maintains a strong financial position with €209.4 million in cash, providing a runway into 1Q24.

Pharvaris has released pharmacological data on its novel bradykinin B2 receptor antagonist, PHA121. This compound demonstrates a 20-fold higher potency than icatibant, the only approved injectable B2 antagonist, while offering improved intrinsic clearance and oral bioavailability. The early clinical data indicates rapid absorption and favorable pharmacokinetics in healthy participants. Pharvaris aims to provide an oral treatment for hereditary angioedema (HAE), showcasing PHA121 as the most potent small-molecule antagonist in its category.

Pharvaris (Nasdaq: PHVS) announced participation in three investor conferences in March 2022. The events include:

• BioCapital Europe 2022 on March 10, 2022, at 3:00 PM CET in Amsterdam.
• Oppenheimer 32nd Annual Healthcare Conference via webcast on March 15, 2022, at 8:00 AM ET.
• SVB Leerink Mountain Meeting on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.